CD49d
Is there anything new on the CD49d+ front (treatments, does it still matter, etc.)? It’s been said that “cd49d + makes it more difficult for ibrutinib to do its job,” would this apply to the (BTK) class of treatments (acalabrutinib, etc.)?
CD49d
Is there anything new on the CD49d+ front (treatments, does it still matter, etc.)? It’s been said that “cd49d + makes it more difficult for ibrutinib to do its job,” would this apply to the (BTK) class of treatments (acalabrutinib, etc.)?
nalp, I'm not very familiar with CD49d, but I did find the following article which I believe addresses the question that you asked about other BTKIs, at least acalabrutinib.
High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL)
I was surprised to read that CD49d is expressed in 40 % of CLL patients, and I didn't know that high expression correlates with BTKi resistance. This article sciencedirect.com/science/a... cites a paper suggesting that such resistance may be overcome by treating with combined BTK and PI3K inhibitors.
EDIT
Oops! I gave the wrong link above. The article I meant to refer to, summing up the research, is b-s-h.org.uk/about-us/news/... and the research paper is ncbi.nlm.nih.gov/pmc/articl...
Thanks for your post. See my edited reply for the correct link.